Treatment of hepatocellular carcinoma in Child-Pugh B patients

Digestive and Liver Disease

Volumn 45, Issue 10, 2013, Pages 852-858

  Piscaglia, Fabio ^a   Terzi, Eleonora ^a   Cucchetti, Alessandro ^a   Trimarchi, Chiara ^a   Granito, Alessandro ^a   Leoni, Simona ^a   Marinelli, Sara ^a   Pini, Patrizia ^a   Bolondi, Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Hepatocellular carcinoma; Liver function; Transarterial chemoembolisation; Tumour staging systems

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CHEMOEMBOLIZATION; CHILD PUGH SCORE; EARLY CANCER; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

HEPATOCELLULAR CARCINOMA; LIVER FUNCTION; TRANSARTERIAL CHEMOEMBOLISATION; TUMOUR STAGING SYSTEMS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84883746464     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.03.002     Document Type: Article

References (20)

1. Pugh R.N., Murray-Lyon I.M., Dawson J.L., et al. Transection of the oesophagus for bleeding oesophageal varices. British Journal of Surgery 1973, 60:646-649.
2. Kudo M., Chung H., Osaki Y. Prognostic staging system for hepatocellular carcinoma (clip score): its value and limitations, and a proposal for a new staging system, the Japan integrated staging score (JIS score). Journal of Gastroenterology 2003, 38:207-215.
3. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The cancer of the liver Italian program (clip) investigators. Hepatology 2000;31:840-5.
4. Leung T.W., Tang A.M., Zee B., et al. Construction of the Chinese university prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the cancer of the liver Italian program staging system: a study based on 926 patients. Cancer 2002, 94:1760-1769.
5. Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the bclc staging classification. Seminars in Liver Disease 1999, 19:329-338.
6. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
7. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 easl conference. European association for the study of the liver. Journal of Hepatology 2001, 35:421-430.
8. Raoul J.L., Sangro B., Forner A., et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treatment Reviews 2010, 37:212-220.
9. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of Sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: a phase iii randomised, double-blind, placebo-controlled trial. Lancet Oncology 2009, 10:25-34.
10. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 2008, 359:378-390.
11. Easl-eortc clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology 2012;56:908-43.
12. Golfieri R., Cappelli A., Cucchetti A., et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5cm) hepatocellular carcinomas. Hepatology 2011, 53:1580-1589.
13. Piscaglia F., Bolondi L. The intermediate hepatocellular carcinoma stage: should treatment be expanded. Digestive and Liver Disease 2010, 42:S258-S263.
14. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442.
15. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739.
16. Bolondi L., Burroughs A.K., Dufour J.F., et al. Heterogeneity of patients with intermediate (BCLC b) hcc. Proposal for a subclassification to facilitate treatment decisions. Seminars in Liver Disease 2012, 32:348-359.
17. Cabibbo G., Enea M., Attanasio M., et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010, 51:1274-1283.
18. Kudo M., Izumi N., Kokudo N., et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Digestive Diseases 2011, 29:339-364.
19. Kudo M. Real practice of hepatocellular carcinoma in Japan: conclusions of the Japan Society of Hepatology 2009 KOBE congress. Oncology 2010, 78(Suppl. 1):180-188.
20. Bruix J., Llovet J.M., Castells A., et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998, 27:1578-1583.